ClinicalTrials.gg
TerminatedNCT05083078Updated Jul 26, 2022

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

A Phase 1 interventional study of Guselkumab and Risankizumab in Arthritis, Psoriatic and Healthy, sponsored by Janssen Research & Development, LLC. Terminated at 1 site in Austria. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-26.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

Why this study was terminated
The study was stopped due to unanticipated feasibility constraints.

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.

Enrollment
13th of 14
11 · median 173
Started
2021
with 3 others
Phase 1
Only one
of the 14
Registered
8th of 14
by date
Lead sponsor
9 of 14
Janssen Research & Development, LLC

Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 13th largest by enrollment, is one of 4 that started in 2021, is the only one in phase 1, and was the 8th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing guselkumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the tissue distribution of guselkumab and risankizumab in healthy participants (Part 1) and psoriatic arthritis (PsA) participants (Part 2 and Part 3).

03

Conditions studied

  • Arthritis, Psoriatic
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1:

  • Healthy on the basis of physical examination, medical history, vital signs, and 12-lead (ECG) performed at screening. Any abnormalities, must be considered not and this determination must be recorded in the participant's source documents and initialed by the investigator
  • Has a negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease 2019 [COVID-19]) reverse transcription polymerase chain reaction (RT-PCR) test within 72 hours prior to study intervention administration
  • Body weight within 50 kilograms (kg) to 100 kg and (BMI) within the range 18 kilograms per meter square (kg/m\^2) to 30 kg/m\^2 (inclusive)

Parts 2 and 3:

  • Have a diagnosis of psoriatic arthritis (PsA) for at least 3 months before the first administration of study agent and meet classification criteria for psoriatic arthritis (CASPAR) at screening
  • Have active plaque psoriasis

Exclusion criteria

Exclusion Criteria:

Part 1:

  • History or current signs and symptoms of liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, genitourinary, or metabolic disturbances
  • Had major illness or surgery (example, requiring general anesthesia) within 12 weeks before screening, or will not have fully recovered from illness or surgery, or has surgery planned during the time the participant is expected to participate in the study or within 21 weeks after the last dose of study intervention administration

Parts 2 and 3:

  • History or current signs and symptoms of severe, progressive, or uncontrolled liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of PsA), psychiatric, genitourinary, or metabolic disturbances
  • A nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Part 1: Healthy Participants-Coadministration

    Healthy participants will receive a single co-administered dose of risankizumab and guselkumab subcutaneously (SC) on Day 1.

    Drug: Guselkumab · Drug: Risankizumab

  • Experimental
    Part 2: Psoriatic Arthritis (PsA) Participants-Coadministration

    Participants with PsA will receive a single co-administered dose of risankizumab and guselkumab SC on Day 1 and Day 29.

    Drug: Guselkumab · Drug: Risankizumab

  • Experimental
    Part 3: PsA Participants-Separate Administration

    Participants with PsA will receive a single dose of either risankizumab or guselkumab SC on Day 1 and Day 29.

    Drug: Guselkumab · Drug: Risankizumab

Interventions

  • Guselkumab will be administered subcutaneously.

    Also known as: Tremfya, CNTO1959

  • Risankizumab will be administered subcutaneously.

    Also known as: Skyrizi

06

What researchers measure

Primary outcomes

  1. Parts 1 , 2 and 3: Skin Tissue versus Serum Concentration Ratio

    Skin tissue versus serum concentration ratio will be summarized.

    Time frame: Up to Week 12

  2. Part 1: Colon Tissue versus Serum Concentration Ratio

    Colon tissue versus serum concentration ratio will be summarized.

    Time frame: Up to Week 8

  3. Parts 2 and 3: Colon Tissue versus Serum Concentration Ratio

    Colon tissue versus serum concentration ratio will be summarized.

    Time frame: Up to Week 4

  4. Parts 2 and 3: Synovial Tissue versus Serum Concentration Ratio

    Synovial tissue versus serum concentration ratio will be summarized.

    Time frame: Up to Week 12

Secondary outcomes

  1. Parts 1, 2 and 3: Maximum Observed Serum Concentration (Cmax) of Guselkumab and Risankizumab

    Cmax is defined as maximum observed serum concentration.

    Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24

  2. Parts 1, 2 and 3: Time to Reach Maximum Observed Serum Concentration (Tmax) of Guselkumab and Risankizumab

    Tmax is defined as time to reach maximum observed serum concentration.

    Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24

  3. Parts 1, 2 and 3: Area Under the Serum Concentration Versus Time Curve from Time Zero to the Time Corresponding to the Last Quantifiable Concentration (AUC[0-last]) of Guselkumab and Risankizumab

    AUC(0-last) is defined as area under the serum concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration.

    Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24

  4. Parts 1, 2 and 3: Area Under the Plasma Concentration-time Curve from Time 0 to infinity (AUC[0 - Infinity]) of Guselkumab and Risankizumab

    AUC(0-infinity) is defined as area under the plasma concentration-time curve from time 0 to infinity with extrapolation of the terminal phase.

    Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24

  5. Parts 1, 2 and 3: Terminal Half-life (T1/2)

    T1/2 is defined as terminal half-life.

    Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24

  6. Parts 1, 2 and 3: Apparent Total Clearance (CL/F) of Guselkumab and Risankizumab

    CL/F is defined as apparent total systemic clearance after extravascular administration.

    Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24

  7. Parts 1, 2 and 3: Apparent Volume of Distribution Based on Terminal Phase (Vz/F) of Guselkumab and Risankizumab

    Vz/F is defined as apparent volume of distribution based on terminal phase after extravascular administration.

    Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24

  8. Parts 1, 2 and 3: Number of Participants with Antibodies to Guselkumab and Risankizumab

    The detection and characterization of antibodies to guselkumab and risankizumab will be performed using a validated assay method.

    Time frame: Part 1: Up to Week 16, Parts 2 and 3: Up to Week 24

07

Study locations

1 site
  • Medical University Graz
    Graz, 8010, Austria
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jul 2022, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2021
First posted
Oct 19, 2021
StartActual
Nov 4, 2021
Primary completionActual
Jul 1, 2022
CompletionActual
Jul 1, 2022
Last update
Jul 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05083078
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Nov 4, 2021
Primary completion
Jul 1, 2022
Completion
Jul 1, 2022
Last update
Jul 26, 2022

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Guselkumab · Risankizumab

Start the discussion